Advertisement

Topics

Novartis files migraine drug with EMA

07:54 EDT 21 Jun 2017 | pharmaphorum

Novartis has filed its migraine drug erenumab with the EMA, putting it in pole position among a group of pharma companies racing to develop a new class of drugs to treat the debilitating condition. The Swiss drug company said erenumab is the first...

Original Article: Novartis files migraine drug with EMA

NEXT ARTICLE

More From BioPortfolio on "Novartis files migraine drug with EMA"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...